---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-027951"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T02:12:29.802611+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics reports FY2023 net loss $21.5M; cash runway into Q3 2025

## Summary
- FY2023 revenue $8.9M, down 39% from $14.7M in 2022; net loss $21.5M ($0.12/sh).
- Q4 2023 net loss $4.8M ($0.03/sh); total operating expenses $8.2M.
- Cash $35.5M at 12/31/23 plus $13.8M net from Feb 2024 offering; funds operations into Q3 2025.
- OpRegen Phase 2a for dry AMD ongoing with Roche/Genentech; OPC1 IND cleared for spinal cord trial.
- Initiated hypoimmune iPSC cell line for neurology under Eterna Therapeutics collaboration.

## SEC filing metadata
- accession: 0000950170-24-027951
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/0000950170-24-027951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/lctx-20240307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-027951
- JSON: https://secwatch.observer/filing/0000950170-24-027951.json
- Plain text: https://secwatch.observer/filing/0000950170-24-027951.txt

## Key facts
- Earnings Releases
  Lineage Cell Therapeutics, Inc. reported three months ended December 31, 2023 results: revenue approximately $2.1 million, net income $4.8 million, EPS $0.03 per share (basic and diluted).
  - Period: three months ended December 31, 2023
  - Revenue: approximately $2.1 million
  - Net income: $4.8 million
  - EPS: $0.03 per share (basic and diluted)
  - Result: reported results
  source text: Revenues: Lineage’s revenue is generated primarily from collaboration revenues and royalties. Total revenues for the three months ended December 31, 2023 were approximately $2.1 million, a net increase of $0.2 million as compared to $1.9 million for the same period in 2022. Operating Expenses: Operating expenses are comprised of research and development (“R&D”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/0000950170-24-027951-index.htm
- Earnings Releases
  Lineage Cell Therapeutics, Inc. reported year ended December 31, 2023 results: revenue $8.9 million.
  - Period: year ended December 31, 2023
  - Revenue: $8.9 million
  - Result: reported results
  source text: Total revenues for the year ended December 31, 2023 were $8.9 million, a decrease of $5.8 million as compared to $14.7 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/0000950170-24-027951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.